All News
Two Week Twitter (6.17.2022)
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Read ArticleEULAR 2022 – Day 4 Report
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Read ArticleLinks:
The Inflammation Reflex (5.20.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.
Read ArticleLinks:
RNL 2022: Spondyloarthritis Spectrum
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.
- Microbiome in Spondyloathritis - Jose Scher, MD
- Axial Psoriatic Arthritis - Philip Mease, MD
- Juvenile Spondyloathritis - Pamela Weiss, MD
Read Article
Can You Reduce Frequency of Methotrexate Monitoring?
Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.
Read ArticleMaking You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read ArticleLinks:
Links:
Biologics for JIA? Not So Fast, Say Insurers
It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor
Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.
Read ArticleLinks:
Links: